Skip to NavigationSkip to content


MSD set to acquire ArQule in deal worth up to $2.7 billion

MSD has revealed its intention to acquire biopharma firm ArQule in a deal worth a potential total of $2.7 billion, valued at $20 per share in cash.

ArQule is a company leveraging kinase inhibitor discovery in the pursuit of new treatments for cancer, among other conditions. The deal means that MSD scoops up the firm’s lead candidate ARQ 531, a Bruton’s tyrosine kinase (BTK) inhibitor currently in development at Phase 2 for the treatment of B-cell malignancies.

Astellas poised to acquire neuromuscular disease specialist Audentes for $3bn all-cash

Astellas Pharma is set to acquire US-based Audentes Therapeutics in an all-cash deal valued at $3 billion in cash, it has been revealed.

The move was unanimously approved by both companies’ Boards of Directors, with the proposed valuation equating to $60 per share – a premium of 110% to Audentes’ share price as of 2 December this year.

MSD scoops up biopharma firm Tilos for $773 million

US-based firm MSD has announced it intends to acquire biopharma firm Tilos Therapeutics, and has signed a deal with the company to this effect, valued to a total of $773 million.

This new deal means that MSD will acquire all outstanding shares of Tilos through a subsidiary, which altogether come to a potential consideration of $773 million, which includes both an upfront payment as well as milestone payments dependent on the achievement of certain developmental and commercial goals.

MSD buys Peloton Therapeutics in deal worth $2.1 billion

MSD has agreed to acquire all outstanding shares in Peloton Therapeutics in a deal worth up to $2.1 billion.

US firm MSD will pay Texas-based biotech Peloton Therapeutics $1 billion upfront and a further $1.15 billion based on the achievement of regulatory and sales milestones.

The acquisition comes as MSD seeks to boost its oncology pipeline with the addition of Peloton’s lead candidate cancer drug PT2977.

Biogen boosts ophthalmology portfolio with $800m acquisition of gene therapy firm Nightstar

Biogen has announced it has inked an agreement to acquire clinical-stage gene therapy firm Nightstar for a total value of $800 million, which breaks down to $2.50 in cash per share after transaction expenses are taken into account.  

Based in London, Nightstar focuses on the development of adeno-associated virus (AAV) treatments for inherited retinal disorders.

Disapproval from top shareholder throws $74bn BMS/Celgene merger into doubt

The news kicked off 2009 with a bang when Bristol-Myers Squibb announced it intended to acquire Celgene for $74 billion, but what could potentially be the biggest pharmaceutical industry merger of all time has been thrown into doubt thanks to a key BMS shareholder.

Top shareholder Wellington Management, which owns around 8% of BMS shares, has announced, in a rare move, that it does not support the prospective deal on the basis that it is a risky and expensive move.

Ipsen shells out $1.31bn to acquire rare disease specialist Clementia Pharmaceuticals

In a bid to boost its rare disease portfolio prospects, Ipsen has revealed its intention to acquire Clementia Pharmaceuticals, with both companies signing an agreement to this effect valued at $1.31 billion.

As part of the deal, Ipsen will pick up Clementia’s palovarotene, an investigational retinoic acid receptor gamma (RARγ) selective agonist developed for the treatment of fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), two rare and disabling bone disorders for which there are no currently available treatments, as well as in other conditions.

Roche set to acquire Spark Therapeutics in $4.8 billion deal

Roche is set to fully acquire gene therapy Spark Therapeutics after entering into a definitive merger agreement, after the Boards of both companies unanimously approved the deal worth $4.8 billion in total equity value on a fully diluted basis.

The deal’s valuation comes at $114.50 per share, representing a premium of 122% based on Spark’s closing price as of 22 February 2019, and includes approximately $500 million of net cash expected at its close.

Takeda completes Shire acquisition

Japanese firm Takeda Pharmaceuticals has successfully completed its acquisition of Shire Plc. The long anticipated deal has propelled the firm into the top ten biggest pharmaceutical companies worldwide.

The $60 billion takeover is expected to nearly double Takeda’s annual consolidated sales to $31.3 billion. With an expanded global reach, Takeda now holds leading positions in both the US and Japan. The company will retain its focus on Oncology, GI, Neuroscience, Rare Diseases and PDT.

AbbVie records an estimated $4billion in impairment charges after failure of cancer drug Rova-T

US firm AbbVie has said that it will record an estimated $4 billion in impairment charges related to the abandonment of the company’s once much anticipated investigational cancer treatment Rova-T.

Having purchased the rights to Rova-T through its high profile acquisition of Stemcentrx, AbbVie announced in December that it would ‘stop enrolment’ into Phase 3 trials for the second-line therapy for advanced small-cell lung cancer.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches